SUMMARY, EXPLANATION AND LIMITATIONS:
Factor XIII or fibrin stabilizing factor is an enzyme of the blood coagulation system that crosslinks fibrin. When thrombin has converted fibrinogen to fibrin, the latter forms a proteinaceous network in which every E-unit is crosslinked to only one D-unit. Factor XIII is activated by thrombin into Factor XIIIa; its activation into Factor XIIIa requires calcium as a cofactor. Factor XIIIa has been identified in platelets, megakaryocytes, and fibroblast-like mesenchymal or histiocytic cells present in the placenta, uterus, and prostate; it is also present in monocytes, macrophages and dermal dendritic cells. Anti-Factor XIIIa has been found to be useful in differentiating between Dermatofibroma (90% (+)), Dermatofibrosarcoma Protuberans (25%(+)) and Desmoplastic Malignant Melanoma (0%(+)). Factor XIIIa positivity is also seen in Capillary Hemagioblastoma (100%(+)), Hemangioendothelioma (100%(+)), Hemangiopericytoma (100%(+)), Xanthogranuloma (100%(+)), Xanthoma (100(+)), Hepatocellular Carcinoma (93%(+)), Glomus Tumor (80%(+)), and Meningioma 80%(+)).
Immunogen: Recombinat protein according to subunit A of human factor coagulation XIII.
Staining pattern: Cytoplasmatic and nuclear.
Positive control: Tissue sample dermatofibroma or placenta.
This antibody is designed for the specific localization of human Factor XIIIa using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.